Long non-coding RNA CASC2 inhibits malignant progression of endometrial cancer by negatively regulating mir-103a-3p/mir-107

Background: Long noncoding RNA CASC2 was first discovered as a tumor suppressor gene in endometrial cancer, but its mechanism is unclear. The purpose of this study was to investigate the effect of CASC2 on endometrial cancer and its mechanism. Methods: We determined the expression of CASC2, miR-103a-3p/miR-107, PLAG1, and IGF2 in endometrial cancer and normal endometrial tissues through TCGA database and PCR analysis. It was subsequently confirmed that CASC2 and miR-103a-3p/miR-107 affect the biological behavior of endometrial cancer cells through a ceRNA mechanism. In addition, we confirmed this in vivo with a nude mouse xenograft model. Results: The expression of CASC2 in endometrial cancer tissues is significantly downregulated, and this downregulation is related to tumor differentiation and affects tumor prognosis. Through cell experiments, it was found that CASC2 combined with miR-103a-3p/miR-107 can affect the biological behavior of endometrial cancer cells. Further research showed that CASC2, as the ceRNA of miR-103a-3p/miR-107, affected the expression of downstream target genes. The above cell experiments were also confirmed with in vivo experiments in a nude mouse xenograft model. Conclusions: CASC2 combined with miR-103a-3p/miR-107 affects the malignant process of endometrial cancer. This study provides a new direction for the diagnosis and treatment of endometrial cancer.